The Role of the Microbiome and of Radiotherapy-Derived Metabolites in Breast Cancer DOI Open Access
Lourdes Herrera‐Quintana, Héctor Vázquez‐Lorente, Rafael Cardoso Maciel Costa Silva

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(21), P. 3671 - 3671

Published: Oct. 30, 2024

The gut microbiome has emerged as a crucial player in modulating cancer therapies, including radiotherapy. In the case of breast cancer, interplay between and radiotherapy-derived metabolites may enhance therapeutic outcomes minimize adverse effects. this review, we explore bidirectional relationship cancer. We explain how composition influences progression treatment response, its treatments influence composition. A dual role for is explored article, highlighting both their benefits potential hazards. By integrating genomics, metabolomics, bioinformatics tools, present comprehensive overview these interactions. study provides real-world insight through studies clinical trials, while innovations such probiotics, dietary interventions are examined to modulate effectiveness. Moreover, ethical considerations patient perspectives discussed, ensuring understanding subject. Towards revolutionizing strategies improving outcomes, review concludes with future research directions. It also envisions metabolite into personalized therapy.

Language: Английский

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug DOI Creative Commons
Alice Njolke Mafe, Dietrich Büsselberg

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 422 - 422

Published: Feb. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Language: Английский

Citations

1
The Role of the Microbiome and of Radiotherapy-Derived Metabolites in Breast Cancer DOI Open Access
Lourdes Herrera‐Quintana, Héctor Vázquez‐Lorente, Rafael Cardoso Maciel Costa Silva

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(21), P. 3671 - 3671

Published: Oct. 30, 2024

The gut microbiome has emerged as a crucial player in modulating cancer therapies, including radiotherapy. In the case of breast cancer, interplay between and radiotherapy-derived metabolites may enhance therapeutic outcomes minimize adverse effects. this review, we explore bidirectional relationship cancer. We explain how composition influences progression treatment response, its treatments influence composition. A dual role for is explored article, highlighting both their benefits potential hazards. By integrating genomics, metabolomics, bioinformatics tools, present comprehensive overview these interactions. study provides real-world insight through studies clinical trials, while innovations such probiotics, dietary interventions are examined to modulate effectiveness. Moreover, ethical considerations patient perspectives discussed, ensuring understanding subject. Towards revolutionizing strategies improving outcomes, review concludes with future research directions. It also envisions metabolite into personalized therapy.

Language: Английский

Citations

3